Single-step antigen loading and TLR activation of dendritic cells by mRNA electroporation for vaccination in stage III and IV melanoma patients.

Trial Profile

Single-step antigen loading and TLR activation of dendritic cells by mRNA electroporation for vaccination in stage III and IV melanoma patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Feb 2012

At a glance

  • Drugs TriMix DC (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Feb 2012 Additional primary endpoints identified and added as reported by ClinicalTrials.gov.
    • 09 Feb 2012 Planned number of patients changed from 34 to 35 as reported by ClinicalTrials.gov.
    • 09 Feb 2012 Planned end date changed from 1 Feb 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top